In the perspective of an anti-HER-3 therapy for this subgroup of patients, we perform preliminary in vitro and in vivo therapeutic study with EV20/MMAF demonstrating that HER-3 expressing CRC cells can be efficiently targeted by an anti-HER-3 ADC armed with a tubulin inhibitor. The gene discussed is ERBB3; the disease is colorectal carcinoma.